Download - NSTEMI AND ANTITHROMBOTICS 2
![Page 1: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/1.jpg)
NSTEMI and antithrombotics
Part II
Dr. Gilbert Boucher
R4 Emergency Medicine
McGill
![Page 2: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/2.jpg)
Last time:
• Review definitions of Non-ST-elevation Myocardial infraction and related items.
• Prognostic factors.
• Current therapies.
![Page 3: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/3.jpg)
Today:
• Finish anticoagulants.– Hirudin
• Gp IIb/IIIa inhibitors.– Their indications…
• Treatment strategies.– Early vs late angio.
• Special groups.
![Page 4: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/4.jpg)
What's New?
October 4 , 2001
Practice Guidelines: Atherosclerotic Cardiovascular Disease
September 1 , 2001
Practice Guidelines: Atrial Fibrillation
April 27 , 2001
Practice Guidelines: Percutaneous Coronary Intervention
April 27 , 2001
Expert Consensus Document: Catheterization Laboratory Standard
April 3 , 2001
Consensus Conference Report: Care of the Patient with Adult Congenital Heart Disease
April 2 , 2001
Expert Consensus Document: Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies
March 1, 2001
Teaching Slides: ACC/AHA Guidelines for the Management of Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction
January 1, 2001
Consensus Conference Report: Mechanical Cardiac Support 2000: Current Applications and Future Trial Design
November 1, 2000
Clinical Competence Statement: Invasive Electrophysiology Studies, Catheter Ablation, and Cardioversion
October 1, 2000
Clinical Competence Statement: Stress Testing
September 1, 2000
Practice Guidelines: Management of Patients with Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction
September 1, 2000
Consensus Conference Report: Myocardial Infarction Redefined—A Consensus Document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction
July 1, 2000
Expert Consensus Document: Electron-Beam Computed Tomography for the Diagnosis and Prognosis of Coronary Artery Disease
June 1, 2000
Training Statement: Adult Cardiovascular Medicine (COCATS) Revised 6/00 Task Force #5: Training in Nuclear Cardiology
www.acc.org
![Page 5: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/5.jpg)
Anticoagulants
• UFH
• LMW heparin
• Hirudin
![Page 6: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/6.jpg)
Hirudin
• Direct thrombin inhibtor.
• For patients with HIT or history of.
• Binds directly to catalytic site of thrombin without going through antithrombin III
• TIMI 7: better than ASA alone in UA…
• Mild improvement compared to UFH but increase in bleeding, no benefit in STEMI.
• Meta-analysis shows OR of 0.90
![Page 7: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/7.jpg)
Platelet GP IIb/IIIa Receptor Antagonists
• Activation of platelets leads to configurational change increasing affinity for fibrin and other ligands
• Necessary final step to platelets aggregation.
• Needs 80% blockade to achieve potent antithrombotic effects
![Page 8: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/8.jpg)
![Page 9: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/9.jpg)
GP IIb/IIIa Receptor Antagonists.
• Abciximab (reopro): non-specific binding– Unclear significance
• Eptifibatide (integrilin), tirofiban (aggrastat): very specific binding achieve >80% within 5 minutes
• Different antagonists can bind at different sites and can paradoxically activates the GPIIb/IIIa receptor– ?what is happening with the oral form.
![Page 10: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/10.jpg)
GP IIb/IIIa Receptor Antagonists
• 4 main studies
• 2 positives
• High-risk features
• 11.7% vs 8.7%,
• 15.7% vs 14.2%
![Page 11: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/11.jpg)
![Page 12: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/12.jpg)
Numbers…
• PRISM:Platelet Receptor Inhibition in Ischemic Syndrome Management.– heparin (non-weight based) vs tiroban X 48hrs
ECG changes or enzymes or very strong hx of CAD
Composite end-point better at 48hr but only trend at 30 days.
MI/death: non-significant at 48 hrs but + at 30 days (3.6 vs 2.3%).
?Playing/fishing for numbers
![Page 13: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/13.jpg)
PRISM: Lancet 1999•
Figure 1: Adjusted hazard ratios (95% CI) for treatment with tirofiban by
troponin I quartiles
•
Figure 2: Event-rate curves
(mortality, myocardial infarction) for 30-day follow-up for patients with + troponin
I
![Page 14: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/14.jpg)
Numbers…• Prism-plus: Platelet Receptor Inhibition in Ischemic
Syndrome Management in Patients Limited by Unstable Signs and Symptoms
• THE study
• ST changes or + enzymes
• Tiroban alone dropped due to too much mortality– 4.6% vs 1.1 and 1.5%??? (remember PRISM study)
• At 7 days, composite end-point: 17.9% vs 12.9%
• 22% CEP reduction at 30 days (absolute 3.8%)
• 19% CEP reduction at 6 months (absolute 4.4%)
![Page 15: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/15.jpg)
Figure 10
![Page 16: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/16.jpg)
Numbers…• PURSUIT: Eptifibatide
– Platelet Glycoprotein IIb/IIIa in Unstable Angina:Receptor Suppression Using Integrilin Therapy.
– 11 000 pts
– + ECG changes or enzymes rise
• Death or MI at 30 days: 15.7% vs 14.2%– 9.1% vs 7.6% at 4 days
– 11.6% vs 10.1% at 7 days
– Major bleed increased by 1.5%
• Cath rate overall: 60%
![Page 17: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/17.jpg)
Real Numbers!
• GUSTO IV:Lancet June 2001
• Abciximab: 7800 pts without PCI
• Same mortality at 30 days: 8-9%
– Despite all sorts of subgroup analysis…
![Page 18: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/18.jpg)
Antithrombotics:1, 2 or 3 agents???
•
![Page 19: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/19.jpg)
![Page 20: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/20.jpg)
Cardiogenic shock… BAD!!!
• Circulation 1999: GUSTO IIb
• 200 pts with NSTEMI and shock– Incidence of 2.5%
• 73% mortality
• But median time to shock 76 hrs…– 9.6 hrs in STEMI
![Page 21: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/21.jpg)
Last words:
• Journal of Emergency Medicine
October 2000:
– “The effect of early ED treatment with GPIIb/IIIa inhibitors has never been formally studied until now”.
– EARLY trial will compare early ED, vs late CCU vs catheterization laboratory
![Page 22: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/22.jpg)
TIMI score• JAMA, August 16, 2000
• Databases of ESSENCE and TIMI11B
• 12 variables, 7 significants– Age > 65yo
– 3 risk factors for CAD
– Prior coronary stenosis of > 50%
– St deviation
– Severe angina symptoms
– ASA use within 7 days
– Elevated serum cardiac markers
![Page 23: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/23.jpg)
Figure 1. TIMI Risk Score Rates of all-cause mortality, myocardial infarction, and severe recurrent ischemia prompting urgent revascularization through 14 days after randomization were calculated for various patient subgroups based on the number of risk factors present in the test cohort (the unfractionated heparin group in the Thrombolysis in Myocardial Infarction [TIMI] 11B trial; n = 1957) (see Table 1). Event rates increased significantly as the TIMI risk score increased (P<.001 by
2 for trend).
•GP IIb/IIIa inh for score 5 or above???
![Page 24: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/24.jpg)
Figure 2. Validation of TIMI Risk Score and Assessment of Treatment Effect According to Score Rates of all-cause mortality, myocardial infarction, and severe recurrent ischemia prompting urgent revascularization through 14 days after randomization were calculated for the enoxaparin and unfractionated heparin groups in the Thrombolysis in Myocardial Infarction (TIMI) 11B trial and the Efficacy and Safety of Subcutaneous Enoxaparin in Unstable Angina and Non-Q-Wave MI trial (ESSENCE), based on the TIMI risk score. The pattern of increasing event rates with increasing TIMI risk score was confirmed in all 3 validation cohorts (P<.001 by
2 for trend). C statistics were 0.65 for the unfractionated heparin group and 0.61 for the enoxaparin group in TIMI 11B; and 0.65 for the unfractionated heparin group and 0.59 for the enoxaparin group in ESSENCE. The rate of increase in events as more risk factors were present was significantly lower in the enoxaparin group in both studies (for TIMI 11B, P = .01; for ESSENCE, P = .03). Positive values for absolute risk difference (ARD) and number needed to treat to prevent 1 event (NNT) indicate calculations favoring enoxaparin, while negative values indicate calculations favoring unfractionated heparin.
![Page 25: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/25.jpg)
As Dr. Lang would said…
• Auto-validation on its own cohort
• Retrospective
• Specific (but large) group
• That would make it a level…4 if we want to use it as a Clinical decision rule to know whether or not to use GP IIb/IIIa inhibitors.
![Page 26: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/26.jpg)
TIMI Risk Calculator For Unstable Angina
In the blue column, please enter the patient's age, and then answer each clinical question with a Y (for yes) or an N (for no). The patient's risk appears at the bottom of the blue column.
TIMI Risk Score for UA/NSTEMI Entry ScoreAge 1History of Hypertension (Y or N) 0History of Diabetes (Y or N) 0Current Smoker (Y or N) 0Hypercholesterolemia (Y or N) 0Family history of Coronary Artery Disease (Y or N) 0Prior angiographic stenosis >50% (Y or N) 0Severe anginal symptoms (>= 2 episodes rest pain in past 24 hrs) (Y or N) 0Use of aspirin within the last 7 days (Y or N) 0Elevated cardiac markers (either CKMB or cardiac troponin) (Y or N) 0ST deviation (horizontal ST depression or transient ST elevation >= 1 mm) (Y or N) 0Total Risk Score (0-7) 1
Risk of Death/MI/Urgent Revascularization by 14 Days (%) 4.70%
![Page 27: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/27.jpg)
Cost $$$$
• Tiroban: 950$/3 days
• Abciximab: 2000$/treatment
– But how come we are almost never using streptokinase anymore… are we reasonable???
![Page 28: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/28.jpg)
What about:Plavix vs GP IIb/IIIa?18.8% vs 16.5%
17.9 vs 12.9%
JUST a thought …
![Page 29: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/29.jpg)
But back to standard of care…The classics: How do we do?
• In-hospital drugs treatment (%), 1998
USA Canada World
Intravenous heparin 79 88 73
Aspirin 91 92 92
B-blockers 57 73 63
Calcium antagonists 59 53 53
Intravenous nitrates 68 40 51
![Page 30: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/30.jpg)
Angio: stat or later• TACTICS: N Engl J Med 2001; 344:1879-1887, Jun 21, 2001
2220 patients, within 48 hours vs selectively
all got ASA, heparin, GPIIb/IIIa inh
15.9% vs 19.4% at 6 months
6% more CABG, 520 extra caths/1100 pts
MI: 4.8% vs 6.9%
• Pre GPIIb/IIIa inhibitors: TIMI3b (1995)
• Early 18.1% vs 16.2% late
• Decr length of stay
• VANQWISH Investigators: 920 pts
• Early 7.8% vs 3.3% late at hospital discharge
![Page 31: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/31.jpg)
More does not equal better
• Lancet 1998; 352: 507–14
• 8 000 pts, various countries (Brazil, USA, Canada, Australia, Hungary, Poland)– 59% vs 21% angio rate
– Same overall MI/death rate: 4.7% at 7 days
• Late angio: decreased rate of overall cardiovascular event (including stroke) despite higher recurrent angina
![Page 32: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/32.jpg)
What do we find anyway on angio…
• Typically shows the following profile: – 1) no severe epicardial stenosis in 10%
to 20%
– 2) 1-vessel stenosis in 30% to 35%
– 3) multivessel stenosis in 40% to 50%
– 4) significant (.50%) left main stenosis in 4% to 10%.
![Page 33: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/33.jpg)
Next: early statin???!!!…
• Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL)
• JAMA April 2001
• 2000 pts
• Atorvastatin 80mg/d between 24 and 96hrs of admission.
• 17.4% vs 14.8% at 4 months, mostly recurrent symptomatic ischemia requiring rehospitalization.
![Page 34: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/34.jpg)
Risk stratification
Noninvasive stress testing in low-risk patients who have been free of ischemia at rest or with low-level activity and of CHF for a minimum of 12 to 24 h. (Level of Evidence: C)
![Page 35: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/35.jpg)
![Page 36: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/36.jpg)
Risk stratification
• Stress test only if free of:– ST-segment abnormalities
– bundle-branch block
– LV hypertrophy
– Intraventricular conduction defect
– Paced rhythm
– Preexcitation
– Digoxin effect.
Otherwise need imaging: echo or thallium…
![Page 37: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/37.jpg)
Special groups
• Women: more atypical symptoms
– ?better outcome in UA then men
• Elderly: More disease
• Diabetics: Increased risk for any ACS
• Post-CABG: low threshold angio
• All same protocols and numbers…
![Page 38: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/38.jpg)
Cocaine users
• Coronary vasospasms– Worsen by minimal atherosclerosis
– Reversed by CCB
– ST-changes in 38% of pts in detox centers
• Detoxify by cholinesterase in liver and plasma– Less available in infants or elderly
• Increased platelets sensibility
• Decrease antithrombin III and protein C
![Page 39: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/39.jpg)
Cocaine users as per AHA
• NTG and CCB for ST changes
• Angio if persistent ST elevation or if thrombus found
– Thrombolysis if not available
• B-blockers if sBp > 150 or HR > 100
– Labetolol preferred
![Page 40: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/40.jpg)
B-blockers for cocaine users???
Annals of Internal Medicine. Jun 1990
30 volunteers
• In cath lab
• Cocaine followed by propranolol
• No change in Hr or BP but:– 50% incr in coronary resistance with 20% decr in flow
No mention of benzos???????
![Page 41: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/41.jpg)
Conclusion
• Troponemia is a bad sign.
• Lots of studies/numbers out there
• Stratification is probably the way to go to target selected population but can we rely on present evidences…
![Page 42: NSTEMI AND ANTITHROMBOTICS 2](https://reader036.vdocuments.site/reader036/viewer/2022081513/555e657dd8b42a34098b47bf/html5/thumbnails/42.jpg)
Questions?